REGN insider filings
REGENERON PHARMACEUTICALS, INC. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-18. Screen REGN transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 16 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 93 legs across 14 filings by 9 insiders — 62,857 shares, $59,162,329 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 34.
- Largest priced transaction: sale of 7,073 shares @ $965.38 ($6,828,133) by SING GEORGE L, filed 2026-11-04.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| SING GEORGE L — Director | 2 | — | 13 legs · 23,129 sh · $22,294,303 | 4 |
| MURPHY ANDREW J — Co-Chief Scientific Officer | 3 | — | 43 legs · 9,158 sh · $8,003,712 | 7 |
| POON CHRISTINE A — Director | 1 | — | 6 legs · 7,830 sh · $7,587,958 | 2 |
| Zoghbi Huda Y — Director | 1 | — | 2 legs · 7,439 sh · $7,219,274 | 2 |
| LAROSA JOSEPH J — EVP General Counsel and Secret | 1 | — | 2 legs · 4,466 sh · $4,311,890 | 3 |
| Pitofsky Jason — SVP Controller | 1 | — | 8 legs · 4,062 sh · $3,827,159 | 6 |
| McCourt Marion — EVP Commercial | 3 | — | 16 legs · 4,044 sh · $3,530,157 | — |
| BROWN MICHAEL S — Director | 1 | — | 1 leg · 1,929 sh · $1,687,875 | 2 |
| Guarini Kathryn — Director | 2 | — | 2 legs · 800 sh · $700,000 | 4 |
| Fenimore Christopher R. — EVP Finance CFO | 1 | — | — | 4 |
Recent insider filings — REGENERON PHARMACEUTICALS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | SING GEORGE L — Director | Sale (S): 1,000 @ $960.26 · Sale (S): 176 @ $956.96 · Sale (S): 359 @ $957.49 · Sale (S): 465 @ $958.11 | EDGAR |
| 2026-11-18 | 4 | MURPHY ANDREW J — Co-Chief Scientific Officer | Option exercise (M): 17,000 @ $381.92 · Tax withholding (F): 11,989 @ $960.02 · Sale (S): 93 @ $949.69 · Sale (S): 74 @ $950.61 · Sale (S): 298 @ $951.75 · Sale (S): 220 @ $952.75 · +13 more | EDGAR |
| 2026-11-18 | 4 | McCourt Marion — EVP Commercial | Sale (S): 44 @ $952.79 · Sale (S): 59 @ $954.46 · Sale (S): 30 @ $955.51 · Sale (S): 22 @ $956.01 · Sale (S): 44 @ $958.47 · Sale (S): 66 @ $959.46 · +7 more | EDGAR |
| 2026-11-06 | 4 | Pitofsky Jason — SVP Controller | Option exercise (M): 1,500 @ $726.53 · Option exercise (M): 1,478 @ $644.54 · Option exercise (M): 905 @ $492 · Sale (S): 439 @ $939.57 · Sale (S): 575 @ $940.46 · Sale (S): 982 @ $941.58 · +8 more | EDGAR |
| 2026-11-05 | 4 | MURPHY ANDREW J — Co-Chief Scientific Officer | Gift (G): 1,054 @ $0 | EDGAR |
| 2026-11-05 | 4 | Zoghbi Huda Y — Director | Option exercise (M): 7,439 @ $380.95 · Sale (S): 6,939 @ $970.42 · Sale (S): 500 @ $971.06 · Option exercise (M): 7,439 (derivative) @ $0 | EDGAR |
| 2026-11-04 | 4 | SING GEORGE L — Director | Option exercise (M): 7,830 @ $376.69 · Option exercise (M): 7,439 @ $380.95 · Sale (S): 1,224 @ $960.57 · Sale (S): 540 @ $961.85 · Sale (S): 2,522 @ $962.61 · Sale (S): 4,338 @ $963.47 · +7 more | EDGAR |
| 2026-11-04 | 4 | Fenimore Christopher R. — EVP Finance CFO | Option exercise (M): 6,000 @ $381.92 · Tax withholding (F): 4,243 @ $950.50 · Gift (G): 15 @ $0 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-11-04 | 4 | POON CHRISTINE A — Director | Option exercise (M): 7,830 @ $376.69 · Sale (S): 218 @ $966.74 · Sale (S): 772 @ $967.38 · Sale (S): 2,499 @ $968.58 · Sale (S): 3,203 @ $969.50 · Sale (S): 937 @ $970.51 · +2 more | EDGAR |
| 2026-11-04 | 4 | LAROSA JOSEPH J — EVP General Counsel and Secret | Option exercise (M): 12,283 @ $381.92 · Tax withholding (F): 8,686 @ $950.50 · Sale (S): 3,939 @ $965.41 · Sale (S): 527 @ $966.11 · Option exercise (M): 12,283 (derivative) @ $0 | EDGAR |
| 2026-11-03 | 4 | Guarini Kathryn — Director | Option exercise (M): 400 @ $719.37 · Sale (S): 400 @ $900 · Option exercise (M): 400 (derivative) @ $0 | EDGAR |
| 2026-11-03 | 4 | BROWN MICHAEL S — Director | Option exercise (M): 1,929 @ $725.89 · Sale (S): 1,929 @ $875 · Option exercise (M): 1,929 (derivative) @ $0 | EDGAR |
| 2026-11-03 | 4 | McCourt Marion — EVP Commercial | Sale (S): 1,132 @ $869.43 | EDGAR |
| 2026-10-15 | 4 | MURPHY ANDREW J — Co-Chief Scientific Officer | Option exercise (M): 17,000 @ $381.92 · Tax withholding (F): 12,853 @ $754.58 · Sale (S): 6 @ $753.76 · Sale (S): 35 @ $755.91 · Sale (S): 16 @ $757.68 · Sale (S): 24 @ $758.16 · +24 more | EDGAR |
| 2026-09-03 | 4 | Guarini Kathryn — Director | Option exercise (M): 400 @ $719.37 · Sale (S): 400 @ $850 · Option exercise (M): 400 (derivative) @ $0 | EDGAR |
| 2026-09-03 | 4 | McCourt Marion — EVP Commercial | Sale (S): 1,215 @ $850 · Sale (S): 1,131 @ $857.39 | EDGAR |
| 2026-08-21 | 4 | LAROSA JOSEPH J — EVP General Counsel and Secret | Option exercise (M): 12,282 @ $381.92 · Tax withholding (F): 9,019 @ $830.15 · Option exercise (M): 12,282 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | Fenimore Christopher R. — EVP Finance CFO | Option exercise (M): 6,283 @ $381.92 · Tax withholding (F): 4,599 @ $813.47 · Option exercise (M): 6,283 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Zoghbi Huda Y — Director | Option exercise (M): 800 @ $376.69 · Sale (S): 800 @ $800 · Option exercise (M): 800 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Guarini Kathryn — Director | Option exercise (M): 400 @ $719.37 · Sale (S): 400 @ $800 · Option exercise (M): 400 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | RYAN ARTHUR F — Director | Sale (S): 200 @ $650.15 | EDGAR |
| 2026-05-04 | 4 | RYAN ARTHUR F — Director | Sale (S): 5 @ $701.76 · Sale (S): 15 @ $702.46 · Sale (S): 24 @ $703.46 · Sale (S): 15 @ $704.28 · Sale (S): 14 @ $705.56 · Sale (S): 7 @ $706.74 · +6 more | EDGAR |
| 2026-04-03 | 4 | RYAN ARTHUR F — Director | Sale (S): 1 @ $771.32 · Sale (S): 3 @ $772.76 · Sale (S): 8 @ $773.59 · Sale (S): 8 @ $774.58 · Sale (S): 14 @ $775.58 · Sale (S): 13 @ $776.62 · +3 more | EDGAR |
| 2026-03-03 | 4 | RYAN ARTHUR F — Director | Sale (S): 7 @ $777.46 · Sale (S): 2 @ $778.30 · Sale (S): 5 @ $779.69 · Sale (S): 3 @ $780.69 · Sale (S): 2 @ $781.21 · Sale (S): 2 @ $782.62 · +7 more | EDGAR |
| 2026-02-23 | 4 | Zoghbi Huda Y — Director | Option exercise (M): 1,638 @ $376.69 · Sale (S): 49 @ $774.68 · Sale (S): 50 @ $775.50 · Sale (S): 53 @ $778.47 · Sale (S): 208 @ $779.55 · Sale (S): 331 @ $780.45 · +7 more | EDGAR |
| 2026-02-11 | 4 | Pitofsky Jason — SVP Controller | Option exercise (M): 1,000 @ $492 · Sale (S): 20 @ $775.95 · Sale (S): 521 @ $776.43 · Sale (S): 391 @ $777.51 · Sale (S): 563 @ $778.35 · Sale (S): 205 @ $779.56 · +7 more | EDGAR |
| 2026-02-11 | 4 | RYAN ARTHUR F — Director | Sale (S): 1 @ $775.63 · Sale (S): 10 @ $776.59 · Sale (S): 57 @ $777.56 · Sale (S): 12 @ $778.53 · Sale (S): 5 @ $779.41 · Sale (S): 1 @ $780.09 · +7 more | EDGAR |
| 2026-01-08 | 4 | Bassler Bonnie L — Director | Option exercise (M): 1,500 @ $374.12 · Sale (S): 1,500 @ $800 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Guarini Kathryn — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Bassler Bonnie L — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Zoghbi Huda Y — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Schenkein David P — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Thompson Craig B. — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | GOLDSTEIN JOSEPH L — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | SING GEORGE L — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | COLES N ANTHONY — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | POON CHRISTINE A — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | RYAN ARTHUR F — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | BROWN MICHAEL S — Director | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | YANCOPOULOS GEORGE — Bd. Co-Chair, President & CSO, Director | Option exercise (M): 28,570 @ $0 · Tax withholding (F): 28,570 @ $772.09 · Option exercise (M): 28,570 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | SCHLEIFER LEONARD S — Bd. Co-Chair, President & CEO, Director | Option exercise (M): 28,570 @ $0 · Tax withholding (F): 28,570 @ $772.09 · Option exercise (M): 28,570 (derivative) @ $0 | EDGAR |
| 2025-12-31 | 4 | SING GEORGE L — Director | Option exercise (M): 9,212 @ $520.01 · Tax withholding (F): 6,188 @ $774.03 · Option exercise (M): 9,212 (derivative) @ $0 | EDGAR |
| 2025-12-11 | 4 | MURPHY ANDREW J — EVP Research | Tax withholding (F): 4,229 @ $701.51 | EDGAR |
| 2025-12-11 | 4 | McCourt Marion — EVP Commercial | Tax withholding (F): 1,021 @ $701.51 | EDGAR |
| 2025-12-11 | 4 | Van Plew Daniel P — EVP & General Mgr, Industrial | Tax withholding (F): 2,552 @ $701.51 | EDGAR |
| 2025-12-11 | 4 | YANCOPOULOS GEORGE — Bd. Co-Chair, President & CSO, Director | Option exercise (M): 146,815 @ $555.67 · Tax withholding (F): 131,874 @ $701.51 · Option exercise (M): 146,815 (derivative) @ $0 | EDGAR |
| 2025-12-11 | 4 | SCHLEIFER LEONARD S — Bd. Co-Chair, President & CEO, Director | Option exercise (M): 172,723 @ $555.67 · Tax withholding (F): 155,145 @ $701.51 · Option exercise (M): 172,723 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | McCourt Marion — EVP Commercial | Grant/award (A): 2,476 @ $0 · Tax withholding (F): 1,336 @ $712.94 · Grant/award (A): 12,210 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | Van Plew Daniel P — EVP & General Mgr, Industrial | Grant/award (A): 3,715 @ $0 · Tax withholding (F): 1,906 @ $712.94 · Grant/award (A): 18,315 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | LAROSA JOSEPH J — EVP General Counsel and Secret | Grant/award (A): 2,476 @ $0 · Tax withholding (F): 1,396 @ $712.94 · Grant/award (A): 12,210 (derivative) @ $0 | EDGAR |
Recent 8-K events — REGENERON PHARMACEUTICALS, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 8.01 — Other Events | EDGAR |
| 2026-09-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-06 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-06-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-04-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-08 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-01-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=REGN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs